TRINAMIC
7.11.2016 16:32:35 CET | Business Wire | Press release
Trinamic Motion Control GmbH & Co. KG, a leading supplier of semiconductors, electronics and mechatronic solutions in the fields of motor and motion control, is proud to announce the arrival of a new family of high-performance semiconductor components for stepper motor control. The TMC2208-LA and TMC2224-LA are monolithic components with integrated circuit breakers for up to 1.2A RMS, and optimal power controllers for noiseless, sinusoidal control of the motor phases. Above all, both components were designed with the goal of easy application in mind. Trinamic will present the drives to the public at Electronica 2016, in Hall A4 at booth 513.
"Developers are under increasing pressure to shorten development cycles and bring new products on the market faster," explains Michael Randt, founder and CEO of Trinamic. "Our new family of drivers has been specially developed to help make the development process as short and as simple as possible."
Enhanced by the flexible microPlyer interpolater unit, the components offer a resolution of up to 256 microsteps-per-full-step to achieve perfect sinusoidal control - even with low-resolution motion controllers. Further development of Trinamic's stealthChop technology, which was introduced two years ago, has all but eliminated motor noise at low speeds, making the precise control of stepper motors not only possible, but affordable for application in environments that demand absolute silence, e.g. office buildings and residential areas.
Due to the immense popularity of stealthChop technology, the components have been designed for compatibility with existing 3D printer electronics. With stealthChop there is no need for costly redesign.
Both components feature a step/direction source for fully autonomous operation. Configuration is achieved via digital inputs.
The components will be available at a price of USD 1.22 at quantities of 1000 as a QFN28 (5x5) package in the first quarter of 2017. To accelerate the design process, Trinamic offers complete end-to-end evaluation kits. The development boards are open-source hardware and freely available for use as a reference design.
About Trinamic
Trinamic, headquartered in Hamburg, provides integrated circuits and motor control modules to customers worldwide. The company's application-driven approach and in-depth understanding of their customers' needs allow them to offer solutions which simplify and shorten the design phase, resulting in significant cost savings, decreased resource allocation and a reduced total cost of ownership. Trinamic's customers benefit from the company's rich expertise in motor physics and extensive portfolio of intellectual property (IP) acquired through many years of applied experience and success. Product development at Trinamic focuses entirely on miniaturizing form factor, increasing efficiency and maximizing the safety and reliability of their products and, thereby, the systems in which they're used.
The company is fully committed to providing energy efficient solutions. Industry-leading technologies such as Trinamic's patented coolStep™ products offer user-friendliness, precise stepper motor control and, above all, energy savings.
The Trinamic Motion Control Language (TMCL) facilitates the development of motor control applications, enabling shorter development cycles and rapid product release.
Over 20 years of experience and a traditional German ownership structure with private shareholders ensure the long-term availability of their products and components.
From the headquarters in Hamburg, Germany, Trinamic products are sold via a worldwide distribution network.
Printable graphics and an English-language version of this press release are available at:
http://www.trinamic.com/company/press/
View source version on businesswire.com: http://www.businesswire.com/news/home/20161107005244/en/
Contact:
Trinamic
Jonas P. Proeger, +49 (0) 40 514 806-0
Marketing
Director
proeger@trinamic.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
